<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945096</url>
  </required_header>
  <id_info>
    <org_study_id>SOOCHOW-HY-2021-1</org_study_id>
    <nct_id>NCT04945096</nct_id>
  </id_info>
  <brief_title>Outcomes of Patients After Allo-HSCT With Decitabine and NAC</brief_title>
  <official_title>Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct this prospective and randomized clinical trial, to evaluate&#xD;
      the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with&#xD;
      decitabine containing conditional regimen and NAC treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main curative treatment&#xD;
      for hematological malignancy. Relapse, graft versus host disease (GVHD) and graft failure are&#xD;
      the main causes of treatment failure. Acetylcysteine (NAC) was found to be able to enhance&#xD;
      defective HSCs by repairing dysfunctional bone marrow endothelial cells, and overcome the&#xD;
      exhaustion of HSCs and enhance the engraftment of HSCs. Decitabine could restore bone marrow&#xD;
      microenvironment by repairing endothelial cells and endothelial progenitor cells, as well as&#xD;
      cytokines and chemokines which are crucial to HSCs proliferation and differentiation, thereby&#xD;
      promote platelet recovery after HSCT. Besides, decitabine therapy was shown to be associated&#xD;
      with reduced incidence of GVHD, lower relapse rate, and increased overall survival in several&#xD;
      studies. Thereby the investigators will conduct this clinical trial to evaluate the&#xD;
      hematopoietic reconstitution, GVHD and relapse rate of patients with hematological malignancy&#xD;
      after allo-HSCT with decitabine containing conditional regimen and NAC treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized after the investigator has verified that all eligibility criteria have been met. Subjects will be randomized in a 1:1 ratio to either Experimental Group (Acetylcysteine + Decitabine) or Active Comparator Group (Standard Treatment).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The hematological engraftment rates</measure>
    <time_frame>1 year</time_frame>
    <description>The hematological engraftment rates of patients after HSCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GVHD rates</measure>
    <time_frame>1 year</time_frame>
    <description>The GVHD rates of patients after HSCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse rates</measure>
    <time_frame>1 year</time_frame>
    <description>The relapse rates of patients after HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the overall survival (days) of patients after HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the disease free survival (days) of patients after HSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Engraft Failure</condition>
  <condition>Relapse</condition>
  <condition>GVHD</condition>
  <arm_group>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetylcysteine (1.2g twice a day, oral administration, from day -10 to day 365 after HSCT). Conditional regimen: decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen); semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conditional regimen: semustine 250 mg/m2/day on day -9; cytarabine 2 g/m2 every 12 hours on day -8; busulfan 3.2mg/kg/day on day -7 to -5; cyclophosphamide 1.8g/m2/day on day -4 to -3; cyclosporin A: 3mg/kg/d from day -8. Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) and mycophenolate (500mg, oral, twice a day from day -8) were usually added for transplants with unrelated donor or HLA mismatched donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <other_name>5-aza-2'-deoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine</intervention_name>
    <description>Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <other_name>Acetadote</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semustine</intervention_name>
    <description>Semustine: 250 mg/m2/day on day -9.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Methyl-CCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine: 2 g/m2 every 12 hours on day -8.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan: 3.2mg/kg/day on day -7 to -5.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide: 1.8g/m2/day on day -4 to -3.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>Cyclosporin A: 3mg/kg/d from day -8.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Cyclosporine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin</intervention_name>
    <description>Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate</intervention_name>
    <description>Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.</description>
    <arm_group_label>Acetylcysteine + decitabine</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as hematopoietic malignancy;&#xD;
&#xD;
          2. Achieved complete remission since the last chemotherapy;&#xD;
&#xD;
          3. Age 10-70 years；&#xD;
&#xD;
          4. Be willing to receive allo-HSCT, with HLA matched related or HLA matched unrelated, or&#xD;
             HLA mismatched related donor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infections, severe organ damage (cardiac, renal and/or hepatic dysfunction&#xD;
             greater than grade 2 according to the Common Terminology Criteria for Adverse Events&#xD;
             V5.0), or any other conditions that make patients ineligible for allo-HSCT;&#xD;
&#xD;
          2. Allergic to acetylcysteine or decitabine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Han, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaqiong Tang, Dr.</last_name>
    <phone>18896588075</phone>
    <email>tangyaqiong@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yue Han, Prof.</last_name>
    <phone>13901551669</phone>
    <email>hanyue@suda.edu.cn</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Semustine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT04945096/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

